Neuronetics, Inc. STIM
Neuronetics, Inc. (Nasdaq: STIM) is a CNS/neurology/psychiatry drug developer. Its lead program, NeuroStar Advanced Therapy System, is marketed for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Anxious Depression.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NeuroStar System for MDD (adults) | Major Depressive Disorder in adult patients who have failed prior antidepressant medication | device-combination | Approved |
| NeuroStar System for OCD | Obsessive-Compulsive Disorder (adults, adjunct) | device-combination | Approved |
| NeuroStar System for adolescent MDD | Major Depressive Disorder in adolescent patients aged 15-21 | device-combination | Approved |
| NeuroStar System for anxious depression | Anxiety symptoms in adult patients with MDD | device-combination | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.